{"transactions":[{"id":3119205,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":148640,"kind":"person","name":"Almon Einat Brill","position":1,"cik":"0001385116","reported_name":"Almon Einat Brill","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Development Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-08T21:07:44.000Z","date":"2020-06-07","kind":"grant","acquired":true,"shares":196995,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 25,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025; and (ii) options to purchase 70,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2025."}],"balance_after":196995,"derivative":{"exercise_price":3.59,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":196995},"source":{"system":"sec-edgar","filing":"0001104659-20-070906","document":"tm2022027d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920070906/tm2022027d1_4.xml","form_type":"4"}},{"id":3816209,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":148640,"kind":"person","name":"Almon Einat Brill","position":1,"cik":"0001385116","reported_name":"Almon Einat Brill","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Product Development"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-14T20:31:21.000Z","date":"2018-09-13","kind":"grant","acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (ii) options to purchase 250,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025."}],"balance_after":700000,"derivative":{"exercise_price":0.56,"expiration_date":"2028-09-13","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001144204-18-049522","document":"tv502883_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420418049522/tv502883_4.xml","form_type":"4"}}]}